Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Filtronic

    MCap

    GBP107m

    Last close

    GBP0.48

    ▲ −1.50 (−3.06%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

VolitionRx – executive interview

VolitionRx – executive interview

VolitionRx is a multinational epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

In this video, CEO Cameron Reynolds, CFO Terig Hughes and Dr Tom Butera, CEO of Volition Veterinary Diagnostics Development, discuss the company’s Q221 financial and operational results and provide a business update. The company made significant progress with multiple programs in 2021 and is very well positioned financially, with cash and cash equivalents of approximately $27.9m at 30 June 2021.

< Previous
Next >

You may also be interested in these:

TMT

Checkit – executive interview

Investment Companies

International Public Partnerships - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free